|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Comparison of subconjunctivally injected bevacizumab, ranibizumab, and pegaptanib for inhibition of corneal neovascularization in a rat model显示文摘AIM: To compare the efficacies of subconjunctival bevacizumab, ranibizumab, and pegaptanib sodium injections for the inhibition of corneal neovascularization in an experimental rat model. METHODS: Sixteen corneas of 16 rats were chemically cauterized and randomized into four groups: bevacizumab group that treated with 0.05mL/1.25mg bevacizumab, ranibizumab group that treated with 0.05mL/0.5mg ranibizumab, pegaptanib group that treated with 0.05mL/0.15mg pegaptanib sodium, and control group that treated with 0.05mL saline solution. Digital photographs of the corneas were taken and analyzed using an image analysis software program. All corneas were excised and examined histologically on the 15 th day. RESULTS: Each treatment group had significantly less neovascularized corneal areas and fewer blood vessels than the control group (all P <0.05). In addition, bevacizumab group had significantly less neovascu-larized corneal areas and fewer blood vessels than ranibizumab and pegaptanib groups (both P <0.05). However, there was no significant difference between the ranibizumab and pegaptanib groups regarding percentage of neovascularized corneal areas and number of blood vessels (both P >0.05). CONCLUSION: Subconjunctival bevacizumab, ranibiz-umab, and pegaptanib sodium were effective with no corneal epitheliopathy for inhibiting corneal neovascularization after corneal burn in rats .Bevacizumab was more effective than ranibizumab and pegaptanib sodium. | Ebru Eren Akar Veysi ner Cem Küükerdnmez Yonca Aydin Akova | 2013 | International Journal of Ophthalmology(English edition)2013，6，2： | 9 |
| 2 | Does topical bevacizumab prevent postoperative recurrence after pterygium surgery with conjunctival autografting?显示文摘AIM:To assess the effect of topical bevacizumab use on postoperative pterygium recurrence in eyes who underwent pterygium excision with limbal-conjunctival autograft transplantation(LCAT).METHODS:eighty-eight eyes of 88 patients with primary pterygium were included.Pterygia were graded preoperatively from type 1 to type 3(type 1 atrophic,type3 inflamed)according to the inflammatory status.The eyes were preoperatively randomized to receive topical steroid and antibiotic treatment(group 1,46 eyes)and additional topical bevacizumab(5 mg/mL;group 2,42eyes)in the postoperative period.All eyes underwent pterygium excision and LCAT.Medications were tapered and discontinued at one month.Postoperative complications and recurrence rates were recorded.RESULTS:The mean follow-up duration was 29.3±4.2mo(24-52mo)and 28.5±3.4(24-48mo)in group 1 and2,respectively(P>0.05).There were no statistically significant differences regarding the age or gender between groups(P>0.05).Also,the difference between groups with respect to pterygium type was not significant.During the follow-up period,recurrence developed in 2 eyes(4.3%)in group 1,whereas in one eye(2.4%)in group 2.No statistically significant difference between groups was found in recurrence rates(P>0.05).No re-operation for recurrence was necessary during the follow-up period in both groups.CONCLUSION:Topical bevacizumab seems to have no additonal effect on pterygium recurrence after LCAT. | Aylin Karalezli Cem Kucukerdonmez Yonca A. Akova Bengu Ekinci Koktekir | 2014 | International Journal of Ophthalmology(English edition)2014，7，3： | 3 |
| 3 | Comparison of Conjunctival Autograft With Amniotic Membrane Transplantation for Pterygium Surgery: Surgical and Cosmetic Outcome显示文摘 | Cem Kü?ükerd?nmez Yonca A Akova Dilek Dursun Altn?rs | 2007 | Cornea2007，，4： | 1 |
| 4 | Severe Corneal Changes following Intravitreal Injection of Bevacizumab显示文摘 | Sezin Akca Bayar Dilek D. Altinors Cem Kucukerdonmez Yonca A. Akova | 2010 | Ocular Immunology and Inflammation2010，，4： | 1 |
| 5 | Nasolacrimal Duct Obstruction: Clinicopathologic Analysis of 205 Cases显示文摘 | Rana Altan-Yaycioglu Handan Canan Selcuk Sizmaz Nebil Bal Aysel Pelit Yonca A. Akova | 2010 | Orbit2010，，5： | 1 |
| 6 | Subconjunctival bevacizumab in the impending recurrent pterygia显示文摘 | Sezin Akca Bayar Cem Kucukerdonmez Ozlem Oner Yonca A. Akova | 2014 | International Ophthalmology2014，，3： | 1 |
| 7 | 同一家庭3个姐妹色觉障碍(英文)显示文摘目的:评价我校医学生和她的家庭成员先天色觉障碍的遗传特征,以建立其遗传模式。方法:运用Ishihara(石原)假同色图试验测定色觉障碍,用FW100色调试验评估其类型。并进行眼科检查和遗传学研究,建立色盲家谱,并对她的家庭给予遗传学咨询。结果:眼科检测结果显示双眼最佳矫正视力为20/20(1.0),近视矫正屈光度-2D,裂隙灯检测和眼压测量结果在正常范围,眼底镜检查视神经、黄斑和周边视网膜均正常,其它外眼评估和神经学检测正常,先证者的姐妹和她父母的眼科检测也正常,3姐妹和父亲的IPPT试验错误得分为19~20/25,结果和红绿色盲中绿色觉异常者一致。染色体分析和卵巢周期均正常。结论:根据她家谱,她的色盲是伴X染色体的隐性外显率模式的遗传特征。 | Nimet ünay Gündogan Feride Iffet ■ahin ■ansal Gedik zge Pekdogan Yonca Akova | 2007 | 国际眼科杂志2007，7，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员